PharmGKB contains no prescribing info for this . Contact us to report known genotype-based dosing guidelines, or if you are interested in developing guidelines.
The PMDA package insert for letrozole notes that CYP2A6 slow metabolizers were found to have 2-fold higher mean plasma trough concentrations as compared to extensive metabolizers.
Please note that the information contained within this drug label annotation is available through a collaboration with the Japanese Society of Pharmacogenomics, who provided a translation of the pharmacogenetic information contained in the PMDA package insert.
Excerpts from the letrozole package insert:
Letrozole is metabolized to a pharmacologically-inactive carbinol metabolite, whose glucuronide conjugate is excreted renally, representing the major clearance pathway. In vitro, it has been indicated that letrozole is metabolized by CYP3A4 and CYP2A6 in human liver microsomes.
Following repeated dosing of letrozole 2.5 mg once daily in postmenopausal women with breast cancer, the plasma trough concentration reached a steady state after 4 to 8 weeks of dosing in slow metabolizers (SMs) who were deficient for CYP2A6, the enzyme responsible for drug metabolism, or had a combination of genotypes associated with reduced enzyme activity (CYP2A6*4, CYP2A6*7, CYP2A6*9 and CYP2A6*10) as well as in extensive metabolizers (EMs) who had wild-type genotypes, CYP2A6*1A or CYP2A6*1B; however, the mean plasma trough concentration was approximately 2-fold higher in SMs than in EMs.
For the complete drug label text with sections containing pharmacogenetic information highlighted, see the letrozole package insert (in Japanese).
*Disclaimer: The contents of this page have not been endorsed by the PMDA and are the sole responsibility of PharmGKB.
PharmGKB contains no Clinical Variants that meet the highest level of criteria.
To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the table.
Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.
The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.
The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.
The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page on the appropriate tab.
Links in the "Drugs" column lead to PharmGKB Drug Pages.
The following icons indicate that data of a certain type is available:
- DG Dosing Guideline information is available
- DL Drug Label information is available
- CA High-level Clinical Annotation is available
- VA Variant Annotation is available
- VIP VIP information is available
- PW Pathway is available
[ close ]
|Alternate Names ?||Chemicals ?||
(+ chr strand)
|rs111033610||NC_000019.10:g.40847036A>G, NC_000019.9:g.41352941A>G, NG_008377.1:g.8412T>C, NM_000762.5:c.670T>C, NP_000753.3:p.Ser224Pro, XM_005258568.1:c.517T>C, XP_005258625.1:p.Ser173Pro||
A > G
|rs1137115||NC_000019.10:g.40850376T>C, NC_000019.9:g.41356281T>C, NG_008377.1:g.5072A>G, NM_000762.5:c.51A>G, NP_000753.3:p.Val17=, XM_005258568.1:c.51A>G, XP_005258625.1:p.Val17=, rs3200915, rs58267364||
T > C
|rs12460590||NC_000019.10:g.40875742A>C, NC_000019.9:g.41381647A>C, NG_007960.1:g.12011T>G, NM_000764.2:c.1436T>G, NM_030589.2:c.1283T>G, NP_000755.2:p.Val479Gly, NP_085079.2:p.Val428Gly, XR_935754.1:n.1975T>G, rs75344699||
A > C
|rs140471703||NC_000019.10:g.40846912C>T, NC_000019.9:g.41352817C>T, NG_008377.1:g.8536G>A, NM_000762.5:c.794G>A, NP_000753.3:p.Arg265Gln, XM_005258568.1:c.641G>A, XP_005258625.1:p.Arg214Gln||
C > T
|rs143690364||NC_000019.10:g.40849959C>T, NC_000019.9:g.41355864C>T, NG_008377.1:g.5489G>A, NM_000762.5:c.202G>A, NP_000753.3:p.Val68Met, XM_005258568.1:c.190+278G>A||
C > T
|rs1801272||NC_000019.10:g.40848628A>T, NC_000019.9:g.41354533A>T, NG_008377.1:g.6820T>A, NM_000762.5:c.479T>A, NP_000753.3:p.Leu160His, XM_005258568.1:c.326T>A, XP_005258625.1:p.Leu109His, rs111473904, rs17791931, rs4986890, rs56844942||
A > T
|rs28399433||NC_000019.10:g.40850474A>C, NC_000019.9:g.41356379A>C, NG_008377.1:g.4974T>G, NM_000762.5:c.-48T>G, XM_005258568.1:c.-48T>G, rs386508632, rs58538938||
A > C
|rs28399434||NC_000019.10:g.40850414C>T, NC_000019.9:g.41356319C>T, NG_008377.1:g.5034G>A, NM_000762.5:c.13G>A, NP_000753.3:p.Gly5Arg, XM_005258568.1:c.13G>A, XP_005258625.1:p.Gly5Arg, rs58150319||
C > T
|rs28399435||NC_000019.10:g.40850341C>T, NC_000019.9:g.41356246C>T, NG_008377.1:g.5107G>A, NM_000762.5:c.86G>A, NP_000753.3:p.Ser29Asn, XM_005258568.1:c.86G>A, XP_005258625.1:p.Ser29Asn, rs57299031||
C > T
|rs28399454||NC_000019.10:g.40845362C>T, NC_000019.9:g.41351267C>T, NG_008377.1:g.10086G>A, NM_000762.5:c.1093G>A, NP_000753.3:p.Val365Met, XM_005258568.1:c.940G>A, XP_005258625.1:p.Val314Met, rs57673794||
C > T
|rs28399468||NC_000019.10:g.40843827C>A, NC_000019.9:g.41349732C>A, NG_008377.1:g.11621G>T, NM_000762.5:c.1454G>T, NP_000753.3:p.Arg485Leu, XM_005258568.1:c.1301G>T, XP_005258625.1:p.Arg434Leu, rs386574980||
C > A
|rs376817657||NC_000019.10:g.40844766C>T, NC_000019.9:g.41350671C>T, NG_008377.1:g.10682G>A, NM_000762.5:c.1168G>A, NP_000753.3:p.Glu390Lys, XM_005258568.1:c.1015G>A, XP_005258625.1:p.Glu339Lys||
C > T
|rs4803381||NC_000019.10:g.40851439T>C, NC_000019.9:g.41357344T>C, NG_008377.1:g.4009A>G, NM_000762.5:c.-1013A>G, XM_005258568.1:c.-1013A>G, rs12985612, rs150298687, rs60981283, rs7260262, rs73553054||
T > C
|rs5031016||NC_000019.10:g.40843869A>G, NC_000019.9:g.41349774A>G, NG_008377.1:g.11579T>C, NM_000762.5:c.1412T>C, NP_000753.3:p.Ile471Thr, XM_005258568.1:c.1259T>C, XP_005258625.1:p.Ile420Thr, rs28399466, rs386597406, rs60711313||
A > G
|rs5031017||NC_000019.10:g.40843845C>A, NC_000019.9:g.41349750C>A, NG_008377.1:g.11603G>T, NM_000762.5:c.1436G>T, NP_000753.3:p.Gly479Val, XM_005258568.1:c.1283G>T, XP_005258625.1:p.Gly428Val||
C > A
|rs56113850||NC_000019.10:g.40847202T>C, NC_000019.9:g.41353107T>C, NG_008377.1:g.8246A>G, NM_000762.5:c.655-151A>G, XM_005258568.1:c.502-151A>G, rs60845437||
T > C
|rs56256500||NC_000019.10:g.40848266G>T, NC_000019.9:g.41354171G>T, NG_008377.1:g.7182C>A, NM_000762.5:c.607C>A, NP_000753.3:p.Arg203Ser, XM_005258568.1:c.454C>A, XP_005258625.1:p.Arg152Ser, rs57102233||
G > T
|rs8192720||NC_000019.10:g.40850405G>A, NC_000019.9:g.41356310G>A, NG_008377.1:g.5043C>T, NM_000762.5:c.22C>T, NP_000753.3:p.Leu8=, XM_005258568.1:c.22C>T, XP_005258625.1:p.Leu8=||
G > A
|rs8192725||NC_000019.10:g.40848807A>G, NC_000019.9:g.41354712A>G, NG_008377.1:g.6641T>C, NM_000762.5:c.344-44T>C, XM_005258568.1:c.191-44T>C, rs12973939||
A > G
|rs8192726||NC_000019.10:g.40848591C>A, NC_000019.9:g.41354496C>A, NG_008377.1:g.6857G>T, NM_000762.5:c.493+23G>T, XM_005258568.1:c.340+23G>T, rs61203574||
C > A
|Alternate Symbols:||CPA6; CYP2A|
|PharmGKB Accession Id:||PA121|
|Cytogenetic Location:||chr19 : q13.2 - q13.2|
|GP mRNA Boundary†:||chr19 : 41349441 - 41356360|
|GP Gene Boundary†:||chr19 : 41346441 - 41366360|
UCSC has a Genome Browser that you can use to view PharmGKB annotations for this gene in context with many other sources of information.View on UCSC Browser
CYP2A6 expression and function
Human cytochrome P450 (CYP-450), family 2, subfamily A, polypeptide 6 (CYP2A6) is a monooxygenase enzyme that metabolizes xenobiotic compounds and activates toxins [Articles:19702528, 12171978, 11692077].
CYP2A6 represents approximately 4% of the total CYP-450 enzyme protein content of adult liver microsomes [Article:8035341]. CYP2A6 is also expressed in the lung, trachea, nasal mucosa, and sex organs such as breast [Articles:12171978, 16988941]. CYP2A6 enzyme activity is determined by measuring coumarin 7-hydroxylation [Articles:2334398, 2322567, 10923861, 11038160]. CYP2A6 expression, enzyme function and induction vary considerably between individuals [Articles:2322567, 2334398, 8035341, 12171978, 10923861, 11038160, 9353388, 12919726], and an individual's CYP2A6 enzyme expression and activity may depend on a combination of environmental factors (such as xenobiotic compounds) and genetic factors (including polymorphic variants) [Articles:19702528, 18666753]. Modeling human CYP2A6 activity in rodents has limited utility due to species-specific CYP2A6 ortholog expression patterns and activity profiles - for example, in rats little or no coumarin is 7-hydroxylated, and a CYP2B enzyme metabolizes nicotine to cotinine [Articles:15364544, 11336973, 11911841, 11053537, 12162851, 1680658]. The crystal structure of human CYP2A6 bound to coumarin was originally described in 2005, revealing a smaller active site than other CYP2 enzymes C8 and C9, composed of a hydrophobic cavity ideal for the oxidation of small planar compounds such as coumarin [Article:16086027]. Several structures with the enzyme in complex with different substrates and/or mechanism based inhibitors have been described since (the Protein Data Bank; [Article:19702528]).
The CYP2A6 gene
CYP2A6 was the first gene of the human CYP2A cytochrome subfamily to be cloned and mapped, and was previously known as CYP2A3 (a name now used for the rat ortholog) [Articles:3856261, 3000277, 7678494, 2726448, 2748347, 11692077]. The CYP2A6 gene sits within a cluster of CYP2 genes on chromosome 19 q13.2, thought to have arisen through duplication events, and shares extensive homology with subfamily members CYP2A7 and CYP2A13 [Articles:11692077, 12171978, 19702528]. The gene is composed of 9 exons spanning around 6kb, encoding a protein of 494 amino acids around 49 kDa in size [Articles:2334398, 19702528].
Genetic variation of CYP2A6
The CYP2A6 gene is highly polymorphic, with over 35 different CYP2A6 alleles described thus far, with additional subgroups (see the Human Cytpchrome P450 Allele Nomeclature Committee website) [Article:11692077]. Star (*) nomenclature is used to describe different CYP2A6 alleles, with the "wildtype" reference allele defined as *1 [Article:2322567]. Genetic variants in the CYP2A6 locus include alleles with single nucleotide polymorphisms (SNPs) (for example *2, *9), whole and partial gene deletions (alleles *4A-H), a gene hybrid with CYP2A7 (for example *12) and gene conversions (for example *1B) http://www.cypalleles.ki.se/cyp2a6.htm. The complex genetic architecture of CYP2A6 coupled with its significant homology with other CYP2A genes makes genotyping challenging, particularly when using SNP based arrays [Articles:11692077, 11805739]. Since single amplifications often cannot discriminate between the different CYP2A genes, special amplification and sequencing techniques have been developed for CYP2A6 genotyping, revealing errors in allele characterization in older studies [Articles:10544257, 10999944, 11207029, 11692077, 11805739].
CYP2A6 genotypes are often classified into predicted phenotype groups, describing the effect on enzyme activity, for example 'poor' metabolizer (no active CYP2A6 alleles, homozygous for inactive alleles), 'slow' (one inactive or two decreased activity alleles), 'intermediate' metabolizer (heterozygous with one decreased activity allele and one active allele), 'normal'/ 'extensive' (2 active alleles), or 'ultrarapid'/ 'fast' (>2 active alleles) [Articles:11805739, 21149643, 17112802, 17035386, 15475735]. Studies may also compare reduced (one or more inactive or decreased activity allele) to normal (two active alleles) metabolizers [Articles:20336063, 21747048]. These categories often overlap or differ between studies. In addition, the same polymorphism can have a different effect on the metabolism of different substrates. For example, CYP2A6*18 activity against nicotine is similar to wildtype enzyme, but is reduced for coumarin and tegafur metabolism, in vitro [Article:15900015], and conversely *17 activity against coumarin is similar to wildtype but significantly reduced for nicotine metabolism [Article:18216723]. People with CYP2A6*12 are slow metabolizers of letrozole, but intermediate metabolizers of nicotine [Article:21975350]. Therefore the effect of CYP2A6 polymorphisms on metabolism should be investigated and interpreted in the context of individual substrates [Article:11805739].
Genetic variants in the CYP2A6 gene can result in reduced expression by affecting transcriptional or translational processes [Article:19702528]. For example, a SNP within the TATA box of the CYP2A6 promoter (allele *9) reduces gene transcription [Article:11394901]. The CYP2A6*1B allele differs from *1A by a CYP2A7 gene conversion in the 3' untranslated region (UTR), and correlates with increased CYP2A6 protein expression and activity, likely through increased mRNA stability [Article:16378601]. Individuals homozygous for the *4 gene deletion allele lack detectable CYP2A6 mRNA expression and enzyme activity [Articles:12844137, 11779172].
Wide variation in the frequency of CYP2A6 alleles across ancestral groups is observed. For example, the frequency of CYP2A6*4 alleles ranges from 0-4% in White, 0-2% in Black, 5-15% in Chinese and 17-24% in Japanese populations [Articles:16402128, 15475735, 17130279, 16452582, 10544257, 16952495, 17220563, 15660270, 16891249, 16272956, 11779172, 21205058]. The frequency of the CYP2A6*9 allele ranges from around 5-8% in White, 6-9% in Black, up to 16% in Chinese and 19-21% in Japanese populations [Articles:16402128, 15475735, 17130279, 16452582, 16952495, 17220563, 15660270, 21205058, 11394901, 21521021]. Other alleles are found predominantly in one ethnic group, for example CYP2A6*17 (defined by the variant rs28399454, V365M) is found at a frequency of around 10% in Black individuals, but not identified in White, Korean or Japanese individuals, whereas *7 is found in Asian subjects at a frequency of around 10%, but not White or Black individuals [Articles:16952495, 15592323].
CYP2A6 as an important pharmacogene
Around 3% of the drugs metabolized by CYP-450 enzymes involve CYP2A6 (reviewed in [Article:19702528]). In the sections below, we describe known pharmacogenetic associations between CYP2A6 variants and drugs, further detailed in Table 1 and 2. When examining these associations, it should be taken into account that environmental factors, such as compounds found in food, cigarettes, hormones or therapeutic drugs, can affect CYP2A6 expression, which can therefore influence drug pharmacokinetics and responses [Articles:18666753, 19702528]. Xenobiotics in our diet, such as the flavonoid biochanin A (found in plants), can upregulate CYP2A6 expression in vitro [Article:17340576]. The hormone estrodiol induces CYP2A6 expression via direct binding of the transcription factor ERalpha to a promoter element upstream of the CYP2A6 gene in vitro [Article:17646279], and may explain why CYP2A6 activity is higher in women than men, and higher in women taking oral contraceptives compared to those not taking them [Article:16678549]. The anti-inflammatory drug dexamethasone, via the Glucorticoid Receptor, induces CYP2A6 transcription in human hepatocytes in vitro, by augmentating Hepatocyte Nuclear Factor 4, alpha [Article:17978169], likely explaining the enhanced CYP2A6 activity seen with dexamethasone treatment [Article:10923861]. The anticonvulsant phenobarbital also enhances CYP2A6 enzyme activity in vitro [Articles:10923861, 11038160]. Inhibitors of CYP2A6 enzyme activity include the antibacterial and antifungal agents isoniazid and ketoconazole [Articles:19702528, 18666753, 9143352], and traditional Chinese medicine [Article:20723593]. Identifying environmental and therapeutic compounds that regulate CYP2A6 activity, as well as genetic polymorphisms, may be important for optimal therapeutic efficacy and avoiding adverse drug reactions [Article:19702528].
Another factor is CYP2A6 genotyping. Most drug-response studies group CYP2A6 genotypes into predicted enzyme activity phenotype groups and assess associations compared to *1 homozygotes, because there are many variant alleles found at low frequencies. Some studies use the * allele name without screening for all variants in the allele as defined by the CYP-450 allele nomenclature committee. Therefore individuals may have variants not screened for, or not have all variants conferring an allele. As described previously, the complexity of CYP2A6 in terms of polymorphisms and homology to other genes means that genotyping errors can occur; as knowledge about the gene and its variants increases, genotyping assays should improve, as was seen with CYP2D6. We therefore provide genotyping details in Table 2.
CYP2A6 polymorphisms, nicotine metabolism and cigarette smoking behavior
The vast majority of published work describing the phenotypic effects of CYP2A6 polymorphisms on enzyme activity has been carried out using nicotine as a substrate (Table 1). These studies have revealed important mechanistic consequences of CYP2A6 alleles on nicotine metabolic inactivation and related smoking behaviors, and by characterizing the relationship between CYP2A6) genotypes and enzyme phenotypes provide a starting point for how these polymorphisms may contribute to the observed inter-individual variability in the PK of other CYP2A6 substrates.
Nicotine is extensively metabolized and has a short plasma half-life of around 2 hours [Article:15734728]. Approximately 80% of nicotine is inactivated in vivo into cotinine in a two-step process (see the PharmGKB Nicotine Pathway, Pharmacokinetics) [Articles:22103613, 19184645, 15734728]. CYP2A6 has a predominant role in the oxidation of nicotine to form a nicotine iminium ion, which is subsequently converted to cotinine (COT) by aldehyde oxidase (AOX) [Articles:10350185, 8937855, 19184645, 15734728]. The majority of COT is metabolized to trans-3'-hydroxy-cotinine (3HC) in a reaction exclusively mediated by CYP2A6 [Articles:8937855, 16359169, 8627511]. The ratio of 3HC/COT is often used as a phenotypic marker of CYP2A6 metabolic activity among smokers due to the long half-life of COT and the in vivo formation dependent kinetics of 3HC [Articles:15229465, 19184645, 15734728].
Nicotine metabolism is subject to large inter-individual variation [Articles:11180041, 8937855], and seven CYP2A6 polymorphisms explain most of the inter-individual variation in nicotine to COT metabolism, in European-Americans [Article:21597399]. Nicotine dependence and cigarette smoking behaviors are closely related to the pharmacokinetics of nicotine, for example cigarette craving negatively correlates with blood levels of nicotine [Article:10899369]. Polymorphisms in CYP2A6 which effect nicotine metabolism have therefore been associated with smoking behaviors (see Table 1) [Articles:10999944, 15564629, 16272956], and are an important consideration in the efficacy of nicotine replacement based smoking cessation treatments [Articles:19184652, 19793020, 19251795]. For example, slow metabolizers (as determined by CYP2A6*2, *4, *9 and *12 alleles), are less likely to be smokers, smoke fewer cigarettes per day, take smaller puff volumes, have lower levels of dependence, are more able to quit, and benefit more from regular and extended nicotine patch replacement therapy compared to normal metabolizers [Articles:15475735, 21212060, 20336063, 16765148, 16402128, 15735609, 14981342, 10999944]. Evidence suggests that CYP2A6 polymorphisms that confer decreased CYP2A6 enzyme activity result in reduced or deficient nicotine metabolism [Articles:10999944, 11180041, 15592323], and this is thought to lead to lower cigarette consumption [Article:17130279]. On the other hand, alleles conferring increased enzyme activity (e.g. duplication or *1B) result in enhanced rates of nicotine metabolism and thus are associated with increased cigarette consumption and depth of inhalation [Articles:10999944, 11180041, 15940289, 11805739, 17130279]. Inhibition of CYP2A6 has therefore been investigated as a smoking cessation treatment [Article:11805739]. In Chronic Obstructive Pulmonary Disease (COPD) patients, CYP2A6 is associated with number of cigarettes smoked per day (cpd) and age of initiation of smoking [Article:21685187]. As smoking cessation is important in preventing COPD progression, identifying patients with risk genotypes for particular smoking behaviors may aid in treatments to help patients reduce smoking [Article:21685187].
The CYP2A6 and CYP2B6 genes are closely localized within the CYP2 cluster on chromosome 19, suggesting potential linkage disequilibrium [Articles:11692077, 16041240]. Human liver CYP2A6 and CYP2B6 enzyme expression is correlated and they share some inducers and substrates (as discussed in [Article:20307138]). Examining the contribution of CYP2B6 genotype on a potentially common substrate (i.e. nicotine, efavirenz) should take into consideration CYP2A6 status, and vice-versa. For example, the association seen between CYP2B6 and nicotine C-oxidation in vitro is abrogated after controlling for CYP2A6 protein levels [Article:20307138].
Table 1: CYP2A6 polymorphisms and nicotine associations
|CYP2A6 allele||Effect on nicotine metabolism||Association with smoking behavior and response to nicotine replacement therapy|
|CYP2A6*1B||Greater nicotine clearance in individuals with alleles *1B1-15 compared to wildtype homozygotes *1A/ *1A [Article:17522595]||Genotype *1B/*1B genotype is associated with increased cpd compared to *1A/*1A, but not significantly associated with smoking status or ability to quit [Article:15940289]. Increased likelihood of being a smoker [Article:14981342]|
|CYP2A6*1X2||1X2A: Higher levels of exhaled carbon monoxide compared to *1/*2, *2/*2, *1/*4, and higher cotinine plasma levels compared to *1/*1 or *1/*2, *2/*2, *1/*4 [Article:10999944]#. 1X2B: increased nicotine metabolism compared to *1/*1 (ns), measured by cotinine/nicotine ratios [Article:17267622]||1X2A: Greater smoking intensity (CO per cpd, COT per cpd) compared to *1/*1 or *1/*2, *2/*2, *1/*4 [Article:10999944]#|
|CYP2A6*2||Longer half-life of nicotine and cotinine, and reduced nicotine metabolism [Article:16952495], [Article:17112802]#||In adolescents, increased risk of becoming nicotine dependent, but slower progression and lower cigarette consumption once dependent [Articles:15564629, 17130279]#. Fewer compared to normal nicotine metabolizers [Articles:15475735, 10999944, 15564629]# [Article:20418888]. Fewer cpd and lower FTND [Article:21747048]#. Increased ability to quit smoking (ns) [Article:19279561]#. Better response to extended transdermal nicotine replacement therapy [Article:20336063]#|
|CYP2A6*4||Reduced nicotine metabolism and altered metabolite profile [Articles:10448083, 15265511, 17220563, 12445030, 16952495]||In adolescents, increased risk of becoming nicotine dependent, but slower progression and lower cigarette consumption once dependent [Articles:15564629, 17130279]#. Reduced risk of being a smoker [Article:14981342], reduced cpd [Articles:21205058, 15308589, 10999944, 15475735, 10999944, 15564629]#, [Articles:12223434, 12832682], and increased ability to quit smoking (ns) [Article:19279561]#. Though in other studies, not significantly associated with smoker status, age started smoking, cpd or ability to quit [Articles:12749606, 11241319, 11725533, 15940289]. Fewer cpd and lower FTND [Article:21747048]#. Better response to extended transdermal nicotine replacement therapy [Article:20336063]#|
|CYP2A6*7||Reduced nicotine metabolism [Articles:16952495, 17220563, 11779172, 12445030, 15900015]. T1412C SNP (rs5031016): Reduced nicotine metabolism [Article:11237731]||Fewer cpd, later onset of smoking, shorter smoking duration, but reduced likelihood of smoking cessation [Articles:21205058, 15308589]#|
|CYP2A6*9||Reduced nicotine metabolism and clearance [Articles:16952495, 12844137], [Article:17112802]#||Fewer cpd [Articles:15475735, 21205058, 21205058, 21747048]#, lower FTND [Article:21747048]#, later onset of smoking, shorter smoking duration, but reduced likelihood of smoking cessation [Article:21205058]#. Better response to extended transdermal nicotine replacement therapy [Article:20336063]#|
|CYP2A6*10||Reduced nicotine metabolism [Articles:16952495, 11779172, 12445030]||Reduced cpd [Articles:21205058, 15308589]#|
|CYP2A6*12||*1/ *12 genotype is associated with normal nicotine metabolism, but *9/*12 is associated with reduced metabolism [Article:17112802]#||Fewer cpd [Articles:15475735, 21747048]#, lower FTND [Article:21747048]#. Better response to extended transdermal nicotine replacement therapy [Article:20336063]#|
|CYP2A6*17||Reduced nicotine metabolism and clearance [Articles:15592323, 16952495]||Increased ability to quit smoking (ns) [Article:19279561]#|
|CYP2A6*35||Reduced nicotine metabolism [Article:19365400]||Increased ability to quit smoking (ns) [Article:19279561]#|
#=studies that analyze combined genotypes, or analyze this allele combined with other alleles in a phenotype category, e.g. reduced activity alleles.
cpd = Cigarettes per day
FTND: Fagerstrom Test for Nicotine Dependence
ns = not significant
CYP2A6 and caffeine
CYP2A6 plays a part in caffeine metabolism, as the major enzyme required to convert paraxanthine (1,7-dimethylxanthine, 17X) into 1,7-dimethyluric acid (17U) via 8-hydroxylation [Article:15980104] (see the PharmGKB Caffeine Pathway, Pharmacokinetics). Human liver microsomes (HLMs) with the CYP2A6 genotype *1/*4, *4/*9 or *1/*9 display significantly reduced 8-hydroxylase enzyme activity against paraxanthine, and *4/*4 samples have undetectable activity, compared to *1/*1 wildtype samples [Article:15980104]. Kinetic assays with CYP2A6 protein fractions demonstrate *7, *10 and *11 alleles confer reduced 8-hydroxylation activity [Article:15980104]. Amongst non-smokers, CYP2A6 intermediate and poor metabolizer genotypes have lower paraxanthine metabolism compared to 'normal metabolizers' (Table 2) [Article:20155256]. In addition to CYP2A6 genotype, cigarette smoking significantly reduces paraxanthine metabolism (17U/ 17X ratio in urine), and may be due to competition between paraxanthine and nicotine [Article:20155256], or via the impact of current smoking status which decreases CYP2A6 activity [Article:11197315]. Therefore, both smoking and CYP2A6 genotype influences CYP2A6 8-hydroxylation activity against caffeine, contributing to the inter-individual variability observed [Article:20155256]. By measuring 17U/17X ratios, caffeine has been proposed as a potentially more suitable substrate for studying the functional effects of CYP2A6 polymorphisms in vivo than nicotine or coumarin [Article:15980104], although further characterization of the timing, dose and association with genotype is required.
CYP2A6 and cancer therapeutics
CYP2A6 has a key role in the metabolism of several drugs involved in cancer treatment. Associations between CYP2A6 genotype, rate of drug metabolism and treatment efficacy are detailed below and in Table 2. CYP2A6 genotype is also associated with risk of developing cancer [Article:19823875], see the 'CYP2A6 and toxicology' section below.
The prodrug tegafur is initially metabolized into 5' hydroxytegafur, which rapidly breaks down into 5-fluorouracil (5 FU) and is further processed into active metabolites with anti-cancer properties (see the PharmGKB Fluoropyrimidine Pathway, Pharmacokinetics and the Fluoropyrimidine (PD) Pathway) [Article:20601926]. Although several CYP-450 proteins have a role in the biotransformation of tegafur into 5 FU, including CYP1A2, CYP2C8, CYP2C9 and CYP1A1, CYP2A6 has a principle role [Articles:11095583, 11106261]. In human liver microsomes, 5 FU formation correlates significantly with coumarin 7-hydroxylation and with CYP2A6 expression [Articles:11095583, 11106261]. Selective inhibition of CYP2A6 activity drastically attenuates 5 FU formation [Articles:11095583, 11106261, 15618749]. Genetic variants that affect CYP2A6 expression and function are associated with altered metabolism of tegafur and clinical outcome. The CYP2A6*4 gene deletion allele significantly reduces CYP2A6 mRNA and protein levels in human liver samples, which correlates with a reduced rate of tegafur metabolism in vitro [Article:21521021] and in vivo the *4C and *11 alleles confer poor tegafur metabolism [Article:12042667]. Conversely, a novel *1B allele is associated with increased CYP2A6 protein expression and significantly higher rates of 5 FU formation in human liver microsome (HLM) samples, compared to samples without the haplotype (Table 2) [Article:21521021].
To optimize 5 FU efficacy and reduce the toxicity of side effects, tegafur is combined with 5-chloro-2,4-dihydroxypyridine (CDHP) (inhibits degradation of 5 FU) and potassium oxonate (prevents gastrointestinal toxicity), to form the oral drug S-1 [Article:8862723]. In cancer patients treated with S-1, genotypes containing CYP2A6*4, *7, *9 and *10 alleles are associated with reduced metabolism of tegafur compared to wildtype CYP2A6, in cancer patients treated with S-1 (Table 2) [Articles:20596643, 21326246, 18212800, 18380793]. Those with two variant CYP2A6 alleles (*4/*4, *4/*7 or *7/*7) have significantly lower oral clearance of tegafur compared to wildtype homozygotes [Article:18380793]. Those without the *4C allele have significantly lower tegafur and higher 5 FU plasma concentrations compared to those with the allele [Article:18212800]. However, other studies find no association between 5 FU plasma concentrations and CYP2A6 genotype, with 5 FU levels correlating instead with CDHP concentrations [Articles:20596643, 18380793].
Examining clinical outcome rather than 5FU blood concentrations suggests that the influence of CYP2A6 genetic variants on tegafur's pharmacokinetics (PK) may have clinical importance. S-1 and cisplatin-treated patients with two CYP2A6 variant alleles *4, *7, *9, *10, or the *1/*4 genotype, have significantly lower treatment response rates, increased risk of disease progression and increased likelihood of reduced overall survival time than other genotypes [Article:21364592]. Similar findings are observed in a study treating patients with S-1 and docetaxel; those with two CYP2A6 variant alleles (*4, *7, *9 or *10) display a 5-fold increased risk of cancer progression [Article:19604090]. However, in this study overall survival is not significantly associated with genotype, possibly due to switching to alternative chemotherapy upon tumor progression (as discussed in [Article:19604090]). Whether the association between CYP2A6 variants and reduced tegafur treatment efficacy is due to reduced formation of 5 FU cannot be concluded due to a lack of parallel PK studies [Articles:19604090, 21364592]. Significantly higher 5 FU plasma concentrations are found in responders to S-1 treatment compared to non-responders, and although no direct significant association between CYP2A6 genotype and treatment response is found in this study, those with one variant CYP2A6 allele have significantly higher 5 FU and significantly lower tegafur plasma concentrations compared to those with two variant alleles [Article:19921195].
Combining these results suggests that a poor-metabolizer CYP2A6 genotype is associated with reduced tegafur metabolism to 5 FU and thus reduced anti-tumor efficacy [Articles:19921195, 21364592, 19604090]. CYP2A6 genotype does not seem to influence treatment side effects, such as hematological toxicity [Articles:19921195, 21364592, 19604090]. Although these associations remain to be investigated further in studies that combine PK and clinical outcome in large sample sizes, current findings suggest that CYP2A6 genotype may be a useful addition to tegafur dosing guidelines to increase treatment efficacy.
Letrozole is a daily oral treatment for estrogen- or progesterone-receptor positive breast cancer in postmenopausal women, and suppresses estrogen synthesis by inhibiting the aromatase enzyme [Article:12802030]. Letrozole plasma levels, elimination rate and clearance show high inter-individual variation, and may contribute to adverse drug reactions or differences in treatment efficacy [Articles:21975350, 21494765]. CYP2A6 has a major role in the breakdown of letrozole into its inactive carbinol metabolite [Articles:19845430, 19198839] (see also the letrozole (Femara) tablet drug label, Novartis Pharmaceuticals Corporation ). In vitro, HLM samples from individuals with CYP2A6 genotypes *1/*4, *4/*4, *4/*9 and *1/*7 have significantly reduced letrozole oxidation compared to *1/*1 wildtype samples [Article:19845430]. Clinical studies in healthy postmenopausal women show that clearance of letrozole is lower in individuals with a CYP2A6 variant allele (*4, *9, *7) compared to *1 (see Table 2) [Article:21494765]. In a cohort of breast cancer patients, CYP2A6 genotype is significantly related to letrozole plasma concentrations, explaining around 26% of the inter-individual variability observed [Article:21975350]. CYP2A6 genotypes defined as conferring slow and intermediate metabolism are associated with significantly higher plasma concentrations of letrozole compared to the wildtype genotype (*1/*1) [Article:21975350] (see Table 2). The ability to predict letrozole plasma concentration using CYP2A6 genotype is further improved by integrating age and body mass index (BMI) variables, explaining 32.3% of inter-individual variation [Article:21975350]. As both CYP2A6 genotype and body weight influence letrozole levels, together they may explain some of the differences in letrozole PK parameters seen between Asian and Caucasian individuals [Article:21494765]. Overall, these studies provide evidence to suggest that CYP2A6 genotyping, along with BMI and age, could be useful for predicting exposure to letrozole in patients [Articles:21975350, 21494765, 19845430].
CYP2A6 and treatment of infectious diseases
CYP2A6 has a role in the metabolism of several drugs involved in the treatment of infectious diseases, as outlined below and detailed in Table 2. When treating individuals for co-infections, such as HIV and malaria infection, the added complication of drug-drug interactions and induction or inhibition of CYP-450 enzymes by these drugs should be considered when assessing the pharmacogenetic effect [Articles:19926036, 21625331].
Efavirenz (EFV) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that suppresses viral replication and is used as a component in highly active anti-retroviral therapy (HAART) regimens for HIV-infected patients [Article:20001610]. High inter-individual variability of EFV plasma levels exists between patients receiving a fixed daily dose, and this has clinical implications; higher EFV plasma levels are associated with increased risk of central nervous system (CNS) side effects, whereas significantly lower levels are associated with failure to suppress viral replication [Articles:15167626, 11192870, 12545140, 19659438]. Demographic factors sex, age, body mass index, or co-medication, cannot explain this variability [Articles:11192870, 12545140, 19659438], and instead genetic variants underlie a high proportion of the inter-individual variation in EFV plasma concentrations (discussed below). Genotyping may therefore aid EFV dosing, help avoid virolic failure and CNS related adverse reactions.
CYP2B6 has a key role in EFV metabolism, predominantly forming the major metabolite 8-hydroxyefavirenz (the product of over 90% of EFV oxidation) [Articles:12676886, 17559344, 19238117], and a high percentage of inter-individual variation in EFV PK is attributed to CYP2B6 genetic variation [Articles:19225447, 19371316, 19779319, 20860463, 15864119, 19659438, 19238117]. CYP2B6 and CYP2A6 contribute to the 7-hydroxylation of EFV (represents less than 10% of EFV oxidation) [Articles:17559344, 19238117, 12676886]. CYP2A6 genetic variation therefore also plays a role in the variability of EFV PK seen in patients, the effects of which are particularly prominent in CYP2B6 slow metabolizers [Articles:19225447, 19238117, 19371316]. These studies are detailed below and in Table 2.
In small studies of 50-65 individuals, there is no statistically significant association between EFV PK parameters and the SNPs rs8192726 (1836 G>T, *9b) or rs28399454 (5065 G>A, *17) [Articles:20860463, 19371316], though rs8192726 is associated with higher EFV plasma levels when the study size is increased to 94 individuals [Article:19779319]. A trend for higher EFV plasma concentrations in rs28399433 T/G (CYP2A6*1/*9) heterozygotes compared to TT homozygotes does not reach significance after correcting for multiple comparisons in a small study of 45 individuals [Article:19659438]. The lack of significant association in these studies may be due to low allele frequencies of the variants examined, small sample sizes, the relatively smaller contribution of CYP2A6 to EFV PK and/ or a weak association; for instance, in Kwara et al. a significant association between EFV PK parameters and CYP2A6 was observed when individuals with one or more copies of CYP2A6*9b (rs8192726) and CYP2A6*17 (rs28399454) were grouped together, but not when the SNPs were analyzed individually [Article:19371316].
Individuals with two CYP2A6 loss-of-function alleles, two decreased function CYP2A6 alleles, or one of each (Table 2) have significantly higher EFV plasma concentrations, compared to those without these alleles, in individuals carrying CYP2B6 reference alleles [Article:19238117]. Stratifying for both CYP2A6 and CYP2B6 genotype, a trend for lower 7-hydroxy-EFV metabolite levels is seen in patients with two loss of function CYP2B6 alleles and two CYP2A6 loss or decrease function alleles, and higher levels of the CYP-450 independent metabolite N-glucuronide-EFV [Article:19238117]. Individuals with CYP2A6 loss-of-function alleles have lower clearance of EFV, and this is more pronounced in those who also have CYP2B6 loss-of-function alleles [Article:19225447]. In multiple regression analysis, incorporating multiple variants, CYP2A6 rs8192726 and/ or rs28399454 status independently contributes to EFV inter-individual plasma concentrations, accounting for around 10% (8.6-12%), with CYP2B6 rs3745274 genotype TT contributing 36-45.2%, and UGT2B7 *1a genotype also significantly contributing [Articles:19371316, 19779319]. To conclude, genetic variation in the CYP2B6, CYP2A6, CYP3A4 and UGT2B7 genes contributes to inter-individual variation of EFV clearance [Articles:19225447, 19371316, 19779319], and the effect of carrying CYP2A6 loss-of-function alleles on EFV clearance is more pronounced in people who are also CYP2B6 slow metabolizers [Articles:19225447, 19238117, 19371316]. The clinical consequence of CYP2A6 genotypes is not reported in the studies above, although higher plasma concentrations of EFV are associated with both increased viral suppression and increased likelihood of CNS adverse reactions [Articles:11192870, 12545140, 15167626]. The CYP2A6 enzyme may have a role in the metabolism of other HAART drugs prescribed alongside EFV, for example Zidovudine (see the PharmGKB Zidovudine Pathway, PK/PD) [Article:9586947], which could affect overall clinical outcome of viral suppression or adverse drug effects.
Artemisinin and derivatives
Artemisinin and its derivatives are drugs used to fight malaria infection [Articles:19851082, 19926036]. Recombinant CYP2A6 metabolizes artemisinin and CYP2A6 inhibition attenuates the rate of drug disappearance in human microsomes in vitro [Article:10583023]. However, CYP2B6 and CYP3A4 enzymes are thought to have a greater role in artemisinin metabolism [Article:10583023] (see the PharmGKB Artemisinin and Derivatives Pathway, Pharmacokinetics). Artemisinin derivatives (arteether, artemether, artesunate) were developed to enhance drug bioavailability, and are used in combination with a second unrelated slower acting drug, in order to initially rapidly eradicate malaria parasites within red blood cells, and then kill any residual parasites [Articles:19851082, 19926036]. CYP2A6 is the major CYP450 enzyme involved in artesunate metabolism, forming dihydro-artemisinin, which is then inactivated by UGT enzymes (see the PharmGKB Artemisinin and Derivatives Pathway, Pharmacokinetics) [Articles:12920490, 19926036]. Therefore, CYP2A6 alleles which confer loss-of-function or decreased function may affect metabolism of these anti-malarial drugs. However, studies investigating urinary metabolites after dosing with artemisinin or derivatives, and use concurrent coumarin or nicotine probe drugs, see no clear correlation between CYP2A6 genotype and an effect on PK or enzyme activity [Articles:18064444, 18979093]. Artemisinin and derivatives induce CYP2B6 expression [Article:18350255; 12844133], further complicating CYP2A6 association studies. Studies controlling for CYP2B6 status and with larger numbers are therefore required to investigate the clinical implications of CYP2A6 genotype on the metabolism of artemisinin and its derivatives.
CYP2A6 and other therapeutic drugs
The antiepileptic drug valproic acid (VPA) is also used to treat migraines and schizophrenia, and could be a potential anti-cancer drug [Article:20798865]. In vitro studies demonstrate CYP2C9 is the principle enzyme in VPA metabolism, however CYP2A6 contributes to around 50% of VPA 3-hydroxylation in human microsomes [Article:16945988] and can contribute to 4-ene-VPA formation, a metabolite of VPA thought to cause hepatotoxicity [Articles:9353388; 16945988, 3101178, 6437960]. CYP2A6 activity against coumarin is inhibited by VPA treatment, therefore VPA may affect responses to drugs metabolized by CYP2A6 taken concurrently [Article:11736863]. Individuals with the *4 gene deletion allele have significantly increased plasma levels of VPA, likely due to decreased CYP2A6 enzyme metabolic activity, and may result in increased drug exposure [Article:20089352].
Pilocarpine is used for the treatment of glaucoma and xerostomia [Article:17178767]. CYP2A6 is the principle enzyme involved in 3-hydroxypilocarpine formation from pilocarpine in HLMs [Article:17178767]. Poor metabolizers with two inactive CYP2A6 alleles have significantly increased pilocarpine plasma concentrations and a trend for higher excretion in the urine, with concurrent reductions of the metabolite 3-hydroxypilocarpine compared to non-poor metabolizers [Article:18698229]. Despite these significant differences in metabolism, no severe adverse effects are observed, and the authors suggest CYP2A6 poor metabolizers likely use alternative renal clearance pathways [Article:18698229].
SM-12502 is a platelet activating factor (PAF) receptor antagonist and has potential for use in asthma therapy [Article:19075994]. CYP2A6 is the major metabolizer enzyme of SM-12502 in human microsomes in vitro [Article:8627557], and the compound has been used to identify CYP2A6 polymorphisms that confer poor and extensive metabolizer phenotypes in vivo [Article:10087035].
CYP2A6 is involved to a varying extent in the metabolism of numerous other therapeutic drugs (see [Article:19702528] for an extensive list of substrates). These include the antitumour drugs ifosfamide (see the PharmGKB Ifosfamide Pathway, Pharmacokinetics) and cyclophosphamide (see the PharmGKB cyclophosphamide Pathway, Pharmacokinetics), the epilepsy treatments phenytoin (see the PharmGKB Phenytoin Pathway, Pharmacokinetics [Article:11038165]), carbamazepine (see the PharmGKB Carbamazepine Pathway, Pharmacokinetics) [Articles:21738081, 12386121], and losigamone [Articles:8886611, 14704462]. CYP2A6 also has a secondary role in metabolism of the anaesthesia halothane [Article:19442086]. Therefore, CYP2A6 polymorphisms may affect additional pharmaceuticals, however the extent of CYP2A6's role in the metabolism/ clearance of these drugs may be minor and/ or redundant, and other genetic variants including those in CYP-450 genes may play a more prominent role in the overall outcome.
CYP2A6 and toxicology
CYP2A6 polymorphisms have not only been associated with extent of nicotine metabolism and effect on smoking behaviors (as discussed previously and outlined in Table 1), but also with activation of carcinogens from tobacco and xenobiotics [Articles:19018727, 19702528]. Tobacco-specific nitrosamines, including nitrosamine 4-(methylnitrosamino)
1(3-pyridyl)-1-butanone (NNK) and N-nitrosonornicotine (NNN), are present in tobacco and cigarette smoke, and hydroxlylation by CYP2A6, CYP2A13 and other CYPs activates NNK and NNN into metabolites that can then react with DNA to form adducts [Articles:19018727, 19702528]. CYP2A6 is involved in the activation of herbicides and pollutants such as hexamethylphosphoramide, dichlorobenzonitrile, aflatoxin B1, naphthalene, methyl tert-butyl ether, and N-nitro-sobenzylmethylamine (NBzMA) [Articles:12919726, 19702528], which are also procarcinogens.
CYP2A6 polymorphisms conferring lower enzyme activity are associated with reduced risk of lung, oral, head and neck, and upper aerodigestive cancers, particularly in tobacco users [Articles:19479063, 21791872, 15308589, 17259654, 1940642, 11960911, 19339270]. The association between CYP2A6 and lung cancer is especially prominent among those who smoke 20 or fewer cigarettes per day [Article:21747048]. Higher CYP2A6 enzyme activity is associated with increased risk of pancreatic cancer (adjusted for smoking status) [Article:19454817]. The results of different association studies are mixed, often due to a lack of statistical power or failure to adjust for smoking status and behaviors [Articles:19018727, 19823875]. The relative contribution of CYP2A6 polymorphisms to cancer risk through smoking behavior versus carcinogen activation is difficult to define [Articles:19823875, 11805739, 19018727], though studies controlling for the amount of cigarette exposure suggest that carcinogen bioactivation is a significant contributor [Articles:21747048, 15308589]. Inhibition of CYP2A6 could potentially reduce cancer risk [Articles:19823875, 11805739, 19018727].
Table 2: CYP2A6 polymorphisms and association with therapeutic drug response
|CYP2A6 Allele or Genotype||Details of genotyping||Drug||Association||Reference and study details|
|*1/*4 or *4/*4 or *4/*9 or *1/*9||#||Caffeine||Significantly reduced metabolism of paraxanthine compared to *1/*1 (not detectable in *4/*4 samples)||[Article:15980104] in vitro study, n=42 human liver microsomes|
|*7 or *10 or *11||#||Caffeine||Reduced activity against paraxanthine||[Article:15980104] in vitro study, CYP2A6 transfected into E. coli, fractions then incubated with paraxanthine|
|Intermediate metabolizers: *1A/*4, *1A/*9, *1B1/*4, *1B1/*9 Poor metabolizers: *4/*9, *9/*9||*4: gene deletion *9: g.-48T>G (rs28399433) *1x2 gene duplication, *1B1 gene conversion in 3' region||Caffeine||Reduced metabolism of paraxanthine into 17U compared to extensive metabolizers (*1A/*1A, *1A/*1B1, *1A1/*1B1x2, *1B1/*1B1)||[Article:20155256] n=100 Serbian, healthy volunteers|
|rs8192725||Genotype CC g.1620T>C Intron 2 Method: direct gene sequencing, provide details of primers and #. Reference sequences used: NG_00008.7 and NP_000753.3||Tegafur||Significantly increased mRNA expression and a trend for increased rate of 5 FU formation (ns), compared to genotype TT||[Article:21521021] in vitro, (n=45) Chinese HLM and liver tissue samples|
|rs8192720 Genotype C/T or TT c.22C>T (NM_000762.5) Leu8Leu exon 1||Method: direct gene sequencing, provide details of primers and # Reference sequences used: NG_00008.7 and NP_000753.3||Tegafur||Increased CYP2A6 mRNA expression and an increased rate of 5 FU formation, compared to genotype CC||[Article:21521021] In vitro, (n=45) Chinese HLM and liver tissue samples|
|rs28399433 Genotype G/T or GG g. -48T>G||Method: direct gene sequencing, provide details of primers and #. Reference sequences used: NG_00008.7 and NP_000753.3||Tegafur||A trend for reduced CYP2A6 mRNA and protein expression, and reduced rate of 5 FU formation (ns), compared to genotype TT||[Article:21521021]|
|*4||Allele defined by: CYP2A6 gene deletion. Method: direct gene sequencing, provide details of primers and #. Reference sequences used: NG_00008.7 and NP_000753.3||Tegafur||Significantly reduced CYP2A6 mRNA and protein expression, and significantly reduced rate of 5 FU formation, compared to those without the *4 allele||[Article:21521021] In vitro, (n=45) Chinese HLM and liver tissue samples|
|Two alleles with a gene conversion in the 3' UTR||Method: direct gene sequencing, provide details of primers and #. Reference sequences used: NG_00008.7 and NP_000753.3||Tegafur||Associated with a trend for reduced CYP2A6 expression and a trend for reduced rate of 5 FU formation, compared to those with no alleles with a gene conversion in the 3'UTR||[Article:21521021] In vitro, (n=45) Chinese HLM and liver tissue samples|
|*1B (haplotype 14)||Haplotype defined by: gene conversion in the CYP2A6 3' UTR, and the SNPs 22C>T (rs8192720) and 1620T>C (rs8192725) Method: direct gene sequencing, provide details of primers and #. Reference sequences used: NG_00008.7 and NP_000753.3||Tegafur||significantly increased CYP2A6 mRNA expression, and significantly increased rates of 5 FU formation, compared to those without the allele.||[Article:21521021] In vitro, (n=45) Chinese HLM and liver tissue samples|
|Genotype *1/*1||Sequenced for *9 at -48T>G (rs28399433), *10 at 6600G>T ) rs28399468), *7 at 6558T>C (rs5031016). *4 gene deletion #. Therefore *1 was defined as wildtype with none of the above variants.||S-1 (tegafur, 5-chloro-2,4-dihydroxypyridine and potassium oxonate combination) and oxaliplatin||Associated with increased tegafur metabolism and a trend for higher 5 FU plasma concentrations compared to individuals with one or two variant alleles (*4, *7, *9, *10 combined) (p values were not given), but not associated with increased likelihood of diarrhea or neutropenia.||[Article:21326246] Study: Biliary tract cancer patients, (n=48)|
|*4C and *11 combined||Alleles defined by: *4C: Gene deletion (identical to *4A according to The Human CYP-450 Nomenclature Committee). *11: c.670T>C, g.3391T>C, Ser244Pro (rs111033610). Method: #, amplification of exon 8 to 3'UTR, restriction digest analysis. Amplification and sequencing of exon 5||Tegafur||Reduced metabolism compared to four other patients.||[Article:12042667] A case study of a gastric cancer patient subsequently found to have both alleles, and follow-up in vitro experiments.|
|Allele *7||g.6558T>C (Ile471Thr) (rs5031016) and gene conversion with CYP2A7 in the 3' UTR #||Tegafur||Reduced 5 FU formation rate compared to *1A/*1A||[Article:15900015] In vitro kinetic assays, using transformed E. coli membrane preparations (n=3)|
|Allele *18||Single SNP rs1809810 (g. 5668A>T, Tyr392Phe). Allele specific primers used for genotyping.||Tegafur||Slightly reduced 5 FU formation rate compared to *1A/*1A||[Article:15900015] In vitro kinetic assays, using transformed E. coli membrane preparations (n=3)|
|Allele *19||g.5668A>T (Tyr392Phe) (rs1809810) and g.6354T>C (intron 8), 6558T>C (Ile471Thr) (rs5031016) and gene conversion with CYP2A7 in the 3' UTR. Allele specific primers used for genotyping.||Tegafur||Reduced 5 FU formation rate compared to *1A/*1A||[Article:15900015] In vitro kinetic assays, using transformed E. coli membrane preparations (n=3)|
|Individuals with two variant alleles (*4/*4, *7/*7 or *4/*7)||*4A: # *7: # with some modifications, c.1412T>C, Ile471Thr (rs5031016)||S-1 (tegafur, 5-chloro-2,4-dihydroxypyridine and potassium oxonate combination)||Significantly reduced oral clearance of tegafur, compared to *1/*1||[Article:18380793] n=54 Japanese patients|
|*4C||Alleles defined by: *4C, *7, *9. Method: # amplification||S-1 (tegafur, 5-chloro-2,4-dihydroxypyridine and potassium oxonate combination)||Significantly reduced metabolism of tegafur, compared to individuals without the allele||[Article:18212800] n=46 Japanese patients with non-small-cell lung cancer.|
|Individuals with two variant alleles, (combined genotypes): *4/*4 *4/*7 *4/*9 *7/*9 *9/*9||Alleles defined by: *4: entire gene deletion #, Positions genotyped: g.-48T>G (for *9) (rs28399433), g. 6558T>C (rs5031016 Ile471Thr) (for *7, *10), and g. 6600G>T (rs28399468, Arg485Leu ) (for *10)||S-1 (tegafur, 5-chloro-2,4-dihydroxypyridine and potassium oxonate combination)||Reduced treatment efficacy compared to individuals with one or two wildtype *1 alleles. Increased risk of disease progression and reduced progression-free survival, as measured by significantly reduced probability of tumor response||[Article:19604090] n= 50 Korean patients with metastatic gastric cancer|
|Two variant alleles, (combined genotypes): *4A/*4A *4A/*7 *4A/*9 *7/*7 *7/*9 *9/*9||# (introduction describes *7 as c.1412T>C (rs5031016 Ile471Thr), and *9 as g.-48T>G (rs28399433), and *4 as complete lack of activity.)||S-1 (tegafur, 5-chloro-2,4-dihydroxypyridine and potassium oxonate combination)||Associated with significantly reduced tegafur clearance, compared to *1/*1 or heterozygotes with one variant allele (tegafur plasma concentrations did not correlate with 5 FU concentrations)||[Article:20596643] n=57 Japanese patients with solid tumors.|
|Individuals with two variant alleles, (combined genotypes): *4A/*4A *4A/*9 *4A/*10 *7/*9 *9/*9 *9/*10||Alleles defined by: *4 gene deletion *7: c.1412T>C , Ile471Thr (rs5031016) *9: g.-48T>G (rs28399433)||S-1 (tegafur, 5-chloro-2,4-dihydroxypyridine and potassium oxonate combination)||Associated with higher tegafur and significantly lower 5 FU plasma concentrations compared to heterozygote patients (*1/*4A, *1/*7, *1/*9, *1/*11 combined genotypes). No significant association with adverse effects or treatment response were found||[Article:19921195] n=34 patients with solid tumors.|
|Individuals with one or two variant alleles, (combined genotypes): *4/*7 *4/*9 *4/*10 *9/*9 *1/*4||Alleles defined by: *4 entire gene deletion, positions genotyped: g.-48T>G (rs28399433) (for *9), g.6558T>C (rs5031016 Ile471Thr) (for *7, *10), and g.6600G>T (rs28399468, Arg485Leu ) (for *10). #||S-1 (tegafur, 5-chloro-2,4-dihydroxypyridine and potassium oxonate combination) and cisplatin||Significantly associated with lower response rate, increased risk of disease progression and reduced overall survival time.||[Article:21364592] n=106, Korean patients, with metastatic gastric cancer|
|*1/*4 or *4/*4 or *4/*9 or *1/*7||#||Letrozole||Significantly associated with reduced metabolism compared with *1/*1 wildtype||[Article:19845430] In vitro study using Japanese HLM samples (n=31)|
|*1A/*1A *1A/*1B *1B/*1B||# *4, *7, *9||Letrozole||Increased clearance compared to heterozyogous or homozygous individuals with variant alleles (*4, *9, *7)||[Article:21494765] n=22 healthy Japanese postmenopausal women|
|Slow metabolizers = 2 copies of decrease-of-function alleles (*9, *12) or 1 or 2 copies of loss-of-function alleles (*2, *4, *7, *10, *17, *20, *23-*27, *35) or 1 decrease-of-function allele and 1 loss-of-function allele||# *2: 1799 T>A; *4E: gene deletion (intron 7); *7: 6558 T>C; *9: -48 T>G; *10: 6558 T>C, 6600 G>T; *12: exon 1-2 CYP2A7, exon 3-9 CYP2A6; *17: 5065 G>A; *23: 2161 C>T; *24: 594 G>C; (if *25 is positive then perform *26 & *27 assays) *26: 1711 T>G; *27: 2162-2163 GC>A frameshift; *35: 6458 A>T.||Letrozole||Significantly higher plasma levels of drug compared to normal metabolizers (genotype *1/*1)||[Article:21975350] n=259 mixed population, postmenopausal women with hormone receptor positive breast cancer|
|Intermediate metabolizer = one copy of decrease-of-function alleles *9, *12||# *2: 1799 T>A; *4E: gene deletion (intron 7); *7: 6558 T>C; *9: -48 T>G; *10: 6558 T>C, 6600 G>T; *12: exon 1-2 CYP2A7, exon 3-9 CYP2A6; *17: 5065 G>A; *23: 2161 C>T; *24: 594 G>C; (if *25 is positive then perform *26 & *27 assays) *26: 1711 T>G; *27: 2162-2163 GC>A frameshift; *35: 6458 A>T.||Letrozole||Significantly higher plasma levels of drug compared to normal metabolizers (genotype *1/*1)||[Article:21975350] n=259 mixed population, postmenopausal women with hormone receptor positive breast cancer|
|Two loss-of-function alleles (*2, *4A-F, *5, *34) or two reduced function alleles (*1H, *1J, *7, *9, *10, *12, *13, *15, *17, *19) or one of each||# for novel variants. *1X2A, *1X2B: gene duplication, *1H and *1J rs61663607 g.-745A>G, *2: rs1801272 g.1799T>A *4A *4F: intron 8 gene conversion with CYP2A7 - gene deletion. *5: rs5031017 g.6582G>T, *7, *10, *19: rs5031016 g.6558T>C, *9, *13, *15: rs28399433 g.-48T>G, *17: rs28399454 g.5065G>A, *12: intron 2 gene conversion with CYP2A7, *34: intron 4, gene conversion with CYP2A7||Efavirenz||Reduced EFV metabolism - significantly higher EFV plasma AUC compared to those without variant alleles (in individuals with CYP2B6 reference alleles - please note reference alleles were not stated in the study).||[Article:19238117] n=169 mixed population, HIV-infected individuals, The Swiss HIV Cohort Study. (Please note, the phenotype categories included different allele groupings from those described in [Article:19225447]).|
|loss-of-function alleles (*2, *4) and/ or diminished function alleles (*1H, *1J, *5, *7, *9, *10, *12, *13, *15, *17, *19, *34)||#||Efavirenz||Reduced clearance of the drug irrespective of CYP2B6 status, however more pronounced in homozygotes with CYP2B6 loss-of-function alleles.||[Article:19225447] n=169 mixed population, HIV-infected individuals, The Swiss HIV Cohort Study. (Please note, the phenotype categories included different allele groupings from those described in [Article:19238117]).|
|*9B allele||rs8192726 g.1836G>T (genotyped only rs8192726 and no other SNPs which make up the *9B allele) #||Efavirenz||Slow metabolism of EFV (significantly increased plasma concentrations) compared to those without the allele. CYP2B6 genotype status was not accounted for in the initial analysis.||[Article:19779319] n=94 Ghanaian patients with HIV-infection, some also with TB coinfection. Please note; this was the same study cohort as [Article:19371316] but more patients|
|*17||rs28399454 genotype AA+GA, g. 5065G>A, Val365Met (genotyped only rs28399454 and no other SNPs which make up the *17 allele)||Efavirenz||Not associated with slow metabolism of EFV (not statistically significant higher plasma concentrations) compared to those without the allele. CYP2B6 genotype status was not accounted for in the initial analysis.||[Article:19779319] n=94 Ghanaian patients with HIV-infection, some also with TB coinfection. Please note; this was the same study cohort as [Article:19371316] but more patients|
|*9B and/ or *17||rs8192726 or rs28399454 (genotyped only rs8192726 and rs28399454, and no other SNPs which make up the *9B and *17 alleles)||Efavirenz||Slow metabolism of EFV (significantly increased plasma concentrations) compared to indivduals without the alleles. CYP2B6 genotype status was not accounted for in the initial analysis but in multiple regression analysis, CYP2A6 genotype status independently contributed to EFV variation, along with CYP2B6 and UGT2B7 genotype.||[Article:19779319] n=94 Ghanaian patients with HIV-infection, some also with TB coinfection. Please note; this was the same study cohort as [Article:19371316] but more patients|
|*9B||genotype TG vs GG rs8192726 g.1836G>T (genotyped only this position and no other SNPs which make up the *9B allele)||Efavirenz||Not associated with EFV plasma or cell concentrations (CYP2B6 status not considered in this initial analysis)||[Article:20860463] n=50 a mixed population of patients with HIV-infection.|
|*17||Genotype GA vs GG rs28399454 g.5065 G>A, Val365Met (genotyped only this position and no other SNPs which make up the *17 allele)||Efavirenz||Not associated with EFV plasma concentration, peripheral blood mononuclear cell concentrations or accumulation ratio. (CYP2B6 status was not considered in this initial analysis)||[Article:20860463] n=50 a mixed population of patients with HIV-infection.|
|*9||rs28399433 Genotype T/G||Efavirenz||A trend for higher EFV plasma concentrations compared to genotype T/T (not considering CYP2B6 status), although this was not statistically significant after Bonferroni correction for multiple comparisons.||[Article:19659438] n=45, Haitians of African decent, with HIV-infection.|
|*4||#||Valproic acid||Significantly higher steady state plasma concentrations (reduced metabolism) in individuals with the *4 allele compared to those without the allele||[Article:20089352] n=179 Northern Han Chinese epilepsy patients|
|Genotype *7/*9 or *4A/*7 or *4A/*9 or *4A/*10||# *4A (entire gene deletion), *7: Ile471Thr (rs5031016), *8: Arg485Leu (rs28399468), *9: g.-48T>G (rs28399433), *10: Ile471Thr (rs5031016) and Arg485Leu (rs28399468)||Pilocarpine||Poor metabolism and low clearance.||[Article:18698229] study 1 n=20, study 2 n=8, healthy Japanese individuals administered with a single dose of pilocarpine hydrochloride.|
5 FU = Fluorouracil
AUC = Area Under the Curve
EFV = efavirenz
HLM = Human Liver Microsomes
ns = not statistically significant
SNP = Single Nucleotide Polymorphism
#=give reference to other studies for the method of genotyping.
=refer to genotyping alleles in concordance with the Human Cytpchrome P450 Allele Nomeclature Committee website: CYP2A6
g. = gene nucleotide position according to NG_000008.7 (unless otherwise stated) as given by Human Cytpchrome P450 Allele Nomeclature Committee website: CYP2A6. Please note that this NCBI reference sequence has been removed.
c. = cDNA nucleotide position according to NM_000762.4 (unless otherwise stated) as given by the Human Cytpchrome P450 Allele Nomeclature Committee website: CYP2A6. Please note that this NCBI reference sequence has been updated.
Where possible, dbSNP rsID have been provided for variants, according to links from the Human Cytpchrome P450 Allele Nomeclature Committee website: CYP2A6 or from the cited journal. Please note, due to the reference sequences on the NCBI having been updated from those given by the CYP Allele Nomenclature Committee, the gene and cDNA nucleotide positions on dbSNP may differ, despite being consistent in amino acid position.
The CYP2A6 gene is found on the minus chromosomal strand. Please note that for standardization, the PharmGKB presents all allele base pairs on the positive chromosomal strand, therefore the alleles within our variant annotations and haplotypes will differ (in a complementary manner) from those in this VIP summary that are given on the minus strand as reported in the literature.
|Citation||PharmGKB summary: very important pharmacogene information for cytochrome P-450, family 2, subfamily A, polypeptide 6. Pharmacogenetics and genomics. 2012. McDonagh Ellen M, Wassenaar Catherine, David Sean P, Tyndale Rachel F, Altman Russ B, Whirl-Carrillo Michelle, Klein Teri E.|
Submitted by Ellen M. McDonagh and Catherine Wassenaar (coauthors), Sean P. David, Rachel F. Tyndale, Russ B. Altman, Michelle Whirl-Carrillo, Teri E. Klein. Rewritten and updated 2012. Updated 2011: Sean P. David (PharmGKB), Catherine Wassenaar (PNAT), Rachel Tyndale (PNAT), - update of work by Manki Ho, Jill Mwenifumbo, Ryan Owen (PharmGKB), Rachel Tyndale (PNAT) (originally submitted Feb 28, 2007)
|Variant Summaries||rs1801272, rs28399433, rs28399444, rs28399454, rs28399468, rs5031016, rs8192726|
|Haplotype Summaries||CYP2A6*1B, CYP2A6*1X2, CYP2A6*2, CYP2A6*4, CYP2A6*7, CYP2A6*9, CYP2A6*10, CYP2A6*12, CYP2A6*17, CYP2A6*20|
Haplotypes are derived from the Human Cytochrome P450 (CYP) Allele Nomenclature Database. The Human Cytochrome P450 (CYP) Allele Nomenclature Database states that nucleotide changes listed below are based on NCBI Reference Sequence NG_008377.1. Numbering appears to start at position 5022 in that file (ATG start codon). For questions about nucleotide positions, please contact the Human Cytochrome P450 (CYP) Allele Nomenclature Database directly, as they are the authoritative source on cytochrome P450 nomenclature.
Notes for particular alleles:
- Alleles CYP2A6*1B1-1B17, *5, *7, *8, *10, *19, have a gene conversion in the 3' flanking region.
- Alleles CYP2A6*4A-*4H confer a gene deletion.
- Allele CYP2A6*1X2A is a gene duplication with a breakpoint at intron 8 to the 3'UTR.
- Allele CYP2A6*1X2B is a gene duplication with a breakpoint 5.2-5.6kb downstream from the stop codon.
- Allele CYP2A6*1B3 was formerly named CYP2A6*1C.
- Allele CYP2A6*3 is a CYP2A6/CYP2A7 gene hybrid.
- Alleles CYP2A6*12A-12C have exons 1-2 of CYP2A7 origin and exons 3-9 of CYP2A6 origin.
- Allele CYP2A6*34 has exons 1-4 of CYP2A7 origin and exons 5-9 of CYP2A6 origin.
- CYP2A6*1A (reference haplotype)
All alleles in the download file are on the positive chromosomal strand. PharmGKB considers the first haplotype listed in each table as the reference haplotype for that set.
PharmGKB Curated Pathways
Pathways created internally by PharmGKB based primarily on literature evidence.
Acetaminophen Pathway (therapeutic doses), Pharmacokinetics
Stylized diagram showing acetaminophen metabolism and transport in the liver.
Acetaminophen Pathway (toxic doses), Pharmacokinetics
Stylized diagram showing acetaminophen metabolism at higher acetaminophen doses (toxic doses) in the liver
Artemisinin and Derivatives Pathway, Pharmacokinetics
Genes involved in the pharmacokinetics of the antimalarial drugs artemisinin, arsenate, artemether, and arteether.
Caffeine Pathway, Pharmacokinetics
Stylized liver cell showing candidate genes involved in the metabolism of caffeine.
Carbamazepine Pathway, Pharmacokinetics
Stylized liver cell depicting candidate genes involved in the pharmacokinetics of carbamazepine.
Cyclophosphamide Pathway, Pharmacokinetics
Model human liver cell showing genes involved in the metabolism of cyclophosphamide.
Efavirenz Pathway, Pharmacokinetics/Pharmacodynamics
Schematic representation of efavirenz metabolism and mechanism of action against HIV.
Fluoropyrimidine Pathway, Pharmacokinetics
Representation of the metabolic pathways for fluoropyrimidines.
Ifosfamide Pathway, Pharmacokinetics
Model human liver cell showing genes involved in the metabolism of ifosfamide.
Nicotine Pathway, Pharmacokinetics
Summary of nicotine metabolism in human liver cell.
Phenytoin Pathway, Pharmacokinetics
Genes involved in the metabolism of phenytoin in the human liver cell.
Valproic Acid Pathway, Pharmacokinetics
Graphic representation of the candidate genes involved in valproic acid pharmacokinetics.
Zidovudine Pathway, Pharmacokinetics/Pharmacodynamics
Representation of candidate genes involved in the metabolism of zidovudine and its mechanism of antiviral action.
Publications related to CYP2A6: 208
The following icons indicate that data of a certain type is available:
- DG Dosing Guideline information is available
- DL Drug Label information is available
- CA High-level Clinical Annotation is available
- VA Variant Annotation is available
- VIP VIP information is available
- PW Pathway is available
[ close ]